Thoracic Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Thoracic surgery is the surgical subspecialty concerned with diseases of the chest cavity excluding the heart — encompassing the oesophagus, trachea, major airways, mediastinum, pleura, diaphragm, thymus, and chest wall, as well as the lungs themselves. It is frequently practised alongside cardiac surgery as cardiothoracic surgery, though at high-volume cancer centres general thoracic surgery has emerged as a distinct specialty. Procedures range from diagnostic VATS pleural biopsy and mediastinoscopy to complex oncological resections including oesophagectomy, tracheal resection with reconstruction, extended thymectomy, and composite chest wall resection.

The specialty has been transformed by minimally invasive techniques. Video-assisted thoracoscopic surgery (VATS) now enables the majority of lung and mediastinal procedures through small port incisions without rib-spreading thoracotomy. Robotic-assisted thoracic surgery (RATS) using the da Vinci surgical system provides enhanced three-dimensional magnification and wristed instrument dexterity for complex hilar, mediastinal, and oesophageal dissections. Minimally invasive oesophagectomy — combining thoracoscopic chest mobilisation with laparoscopic gastric conduit formation — has replaced open thoracolaparotomy as the standard approach for oesophageal cancer at experienced centres, reducing respiratory complications and hospital stay significantly.

A mandatory multidisciplinary tumour board process guides treatment decisions for all thoracic malignancies. The board includes thoracic surgery, medical oncology, radiation oncology, pulmonology, gastroenterology, interventional radiology, nuclear medicine, and pathology. For oesophageal cancer, staging with CT, PET-CT, and endoscopic ultrasound precedes treatment planning, and neoadjuvant therapy is administered before surgery in most Stage II–III cases. Centralisation to high-volume thoracic centres dramatically reduces operative mortality — in-hospital mortality after oesophagectomy has fallen below 2% at specialist high-volume centres.

Oesophageal cancer is the dominant malignancy in thoracic surgery. Squamous cell carcinoma — prevalent in East and Central Asia, Iran, and sub-Saharan Africa — affects the mid and upper oesophagus; adenocarcinoma — rising in incidence in Western countries due to Barrett's oesophagus from chronic GERD — affects the lower oesophagus and gastro-oesophageal junction. Both are treated with neoadjuvant chemoradiotherapy (CROSS regimen) or perioperative chemotherapy (FLOT) followed by minimally invasive oesophagectomy for resectable localised disease. Thymoma and thymic carcinoma arising from the anterior mediastinum require complete surgical resection via sternotomy or minimally invasive thymectomy; extent of resection and adjuvant therapy is guided by Masaoka-Koga staging.

Thymectomy for generalised acetylcholine receptor antibody-positive myasthenia gravis significantly improves clinical outcomes — reducing immunosuppressant requirements and improving remission rates — even in the absence of thymoma, as demonstrated by the MGTX randomised trial. Tracheal stenosis from prolonged intubation, granulomatosis with polyangiitis, or tumour infiltration requires tracheal resection and primary end-to-end anastomosis — a highly specialised procedure performed at very few global centres. Chest wall sarcomas, radiation-induced chest wall necrosis, and metastatic deposits require en bloc chest wall resection with immediate prosthetic reconstruction. Mediastinal germ cell tumours, lymphomas, and substernal goitres are further conditions requiring thoracic surgical expertise.

For oesophagectomy, candidates must have resectable disease (Stage I–III on PET-CT and EUS staging), adequate cardiopulmonary reserve (FEV1 above 1.5 L, ECOG performance status 0–2), and acceptable nutritional status. Malnourished patients with oesophageal cancer — common due to dysphagia — require pre-operative nutritional optimisation via jejunostomy tube feeding before proceeding to surgery. Borderline candidates with impaired lung function may be optimised through pulmonary rehabilitation and smoking cessation. Contraindications to oesophagectomy include M1 metastatic disease, T4b invasion of unresectable structures (aorta, trachea), prohibitive surgical risk, and severe cachexia.

For thymectomy in myasthenia gravis, patients should have generalised acetylcholine receptor antibody-positive disease confirmed by neurological assessment, with bulbar or respiratory symptoms adequately stabilised on pyridostigmine and immunosuppressants. Plasmapheresis or intravenous immunoglobulin in the perioperative period reduces the risk of post-operative myasthenic crisis. Patients with limited thymoma (Masaoka Stage I–II) are candidates for minimally invasive thymectomy; more advanced disease with pleural or pericardial involvement may require sternotomy and extended resection. Tracheal resection candidates require rigid bronchoscopy and high-resolution CT airway assessment to define the extent of stenosis and ensure a sufficient tracheal segment can be preserved proximal to the carina.

Minimally invasive oesophagectomy (MIO) — the current standard at high-volume centres — combines right thoracoscopy for oesophageal mobilisation and mediastinal lymphadenectomy with laparoscopy for gastric conduit formation and pyloroplasty. The gastric conduit is brought up to the chest or neck for anastomosis. Randomised trials (TIME, MIRO) demonstrate equivalent oncological outcomes to open surgery with significantly lower respiratory complication rates, blood loss, and hospital stay. Robot-assisted MIO (Raven procedure) provides enhanced visualisation for precise mediastinal lymph node dissection at robotics-equipped centres.

Thymectomy approaches include trans-sternal extended thymectomy (traditional gold standard), VATS thymectomy (2–3 port right-sided or bilateral approach), and robotic thymectomy. The MGTX trial compared extended trans-sternal thymectomy to prednisone alone in non-thymomatous myasthenia gravis, demonstrating superior three-year remission rates and reduced immunosuppressant requirements with surgery. Chest wall resection for sarcoma or chondrosarcoma involves en bloc removal of involved ribs and soft tissue with immediate reconstruction using titanium rib fixation plates (MatrixRIB system) and polytetrafluoroethylene (PTFE) mesh to restore thoracic rigidity and protect underlying organs. For tracheal stenosis, sleeve resection and primary anastomosis is performed with the neck flexed to reduce anastomotic tension, using absorbable sutures. Video-assisted thoracoscopic surgery (VATS) and robotic thoracic surgery have made lung resection, mediastinal dissection, and oesophageal procedures accessible with small port incisions, two-night hospital stays, and faster return to full activity compared to thoracotomy. Oesophageal resection and primary anastomosis is performed with the neck flexed to reduce anastomotic tension, using absorbable sutures for the cervical anastomosis.

Surgical resection provides the highest probability of long-term cure for resectable thoracic malignancies. After oesophagectomy for Stage II oesophageal cancer following CROSS neoadjuvant chemoradiotherapy, five-year survival ranges from 40–55%; pathological complete responders — approximately 25–30% of patients — achieve five-year survival exceeding 60–70%. For thymoma, surgical resection is curative in Stage I–II disease (ten-year recurrence-free survival above 90%), with the prognosis worsening progressively for Masaoka Stages III–IVb. In myasthenia gravis, thymectomy provides complete stable remission in 30–40% of patients and substantially reduces or eliminates immunosuppressant requirements in an additional 40–50%.

Tracheal resection and reconstruction restores normal airway calibre and eliminates dependence on tracheostomy or repeated dilations in over 90% of carefully selected patients at specialist tracheal surgery centres. Chest wall reconstruction after tumour resection restores thoracic integrity, enables full respiratory mechanics, and provides durable oncological control when R0 margins are achieved. ERAS protocols at high-volume centres have reduced oesophagectomy in-hospital mortality below 2% from the historical rates of 10–15%, representing a dramatic improvement in the safety of this historically feared operation.

Oesophagectomy carries significant perioperative risk even at experienced centres. Respiratory complications — pneumonia (15–25%), pleural effusion, ARDS — remain the dominant source of post-operative morbidity, reflecting the combined impact of thoracic and abdominal surgery, single-lung ventilation, and the aspiration risk from gastric conduit reflux. Anastomotic leak occurs in 8–15% of cases and ranges in severity from a contained radiological finding managed conservatively to a life-threatening mediastinitis requiring immediate reoperation or endoscopic stent placement. Recurrent laryngeal nerve injury — causing hoarseness and aspiration — affects 5–10% of patients after cervical anastomosis.

Post-oesophagectomy stricture at the anastomosis — causing progressive dysphagia — affects 10–25% of patients and is managed by serial endoscopic dilation. Dumping syndrome (early satiation, bloating, diarrhoea after eating) and bile reflux from the gastric conduit cause significant dietary limitation and quality-of-life impairment in the first six to twelve months, gradually improving with dietary adaptation. Chylothorax from thoracic duct injury complicates 1–3% of oesophagectomies. For tracheal surgery, anastomotic dehiscence and restenosis are the critical late complications, requiring bronchoscopic surveillance. Post-operative myasthenic crisis — respiratory failure from neuromuscular weakness — is a rare but potentially fatal complication of thymectomy, managed in the ICU with plasmapheresis and ventilatory support.

After minimally invasive oesophagectomy, patients spend 24–48 hours in the ICU before ward transfer for seven to twelve days. Jejunostomy tube feeding — established at the time of surgery — provides complete nutritional support until a contrast swallow confirms anastomotic integrity at day five to seven, after which oral intake is gradually reintroduced. Patients are discharged on jejunostomy supplements until adequate oral calorie intake is demonstrated at outpatient review. Dietary modifications — small frequent meals, avoidance of recumbency for two hours post-eating, head-of-bed elevation — are lifelong adaptations to prevent conduit reflux and aspiration.

For cancer patients, post-operative CT surveillance begins at three months and continues every six months for three years, then annually. Pathological staging guides the decision for adjuvant chemotherapy or immunotherapy. After thymectomy for myasthenia gravis, neuromuscular status is monitored by the neurologist, with immunosuppressants gradually tapered as clinical remission is established over months to years. Spirometry is performed before and after thymectomy to document any post-operative respiratory impact. For chest wall reconstruction patients, follow-up CT assesses prosthetic stability and monitors for local recurrence. Respiratory physiotherapy, incentive spirometry, and progressive ambulation from day one of surgery are universal ERAS components.

Major thoracic surgery is expensive, reflecting the complexity, ICU requirements, and long post-operative stay. Oesophagectomy in the United States costs USD 80,000–150,000; complex tracheal reconstruction exceeds USD 200,000 at specialist academic centres. UK NHS covers eligible patients without direct cost; private oesophageal surgery costs GBP 40,000–80,000. In India, centres such as Tata Memorial Hospital (Mumbai), Apollo Hospitals, and Fortis Hospitals perform minimally invasive oesophagectomy for USD 8,000–18,000 total, including staging workup, surgery, ICU, and hospitalisation — savings of over 85% versus US costs.

Thailand (Bumrungrad International, Vejthani) charges USD 15,000–28,000 for MIO; Turkey (Acibadem, Medical Park) USD 10,000–20,000. Thymectomy for myasthenia gravis costs USD 25,000–50,000 in the US versus USD 4,000–10,000 in India. Patients travelling internationally for oesophageal cancer surgery should verify that the centre participates in multidisciplinary tumour board processes, has an established VATS or robotic oesophagectomy programme with documented volume, and has clear plans for pathological staging review and adjuvant systemic therapy after surgery. Long-stay family accommodation and post-discharge recovery housing near the hospital are practical considerations for international patients recovering from major thoracic surgery.

Definitive chemoradiotherapy without surgery is an accepted alternative for oesophageal squamous cell carcinoma when surgery is contraindicated or refused, achieving five-year survival rates of 20–30% compared to approximately 40–50% with combined modality treatment including surgery. For early superficial oesophageal cancer (T1a mucosally confined), endoscopic submucosal dissection (ESD) provides curative resection rates above 90% without surgical morbidity. Palliative endoscopic stenting relieves dysphagia in unresectable oesophageal cancer without surgery. Endoscopic balloon dilation and laser resection manage selected cases of benign tracheal stenosis non-surgically. For myasthenia gravis, long-term immunotherapy with steroids, azathioprine, and newer agents such as eculizumab and efgartigimod provides good disease control without surgery, though thymectomy is supported by Level 1 evidence from the MGTX trial and is recommended for eligible patients with generalised MG.